Literature DB >> 3545431

c-myc oncogene expression in colorectal cancer.

K Sikora, S Chan, G Evan, H Gabra, N Markham, J Stewart, J Watson.   

Abstract

The pattern of c-myc gene organization and expression has been examined in resected colonic tumors and in the adjacent normal colon from 15 patients undergoing radical surgery. DNA hybridization showed no evidence of gene amplification or rearrangement. Transcripts of the c-myc messenger ribonucleic acid (mRNA) were elevated up to 32-fold in 12 of 15 tumors. The gene product, p62c-myc, was detected by both immunoblotting and immunohistology using a monoclonal antibody raised against a synthetic peptide immunogen. There was close correlation between c-myc mRNA copy number and p62c-myc abundance. Three well differentiated tumors contained high levels of transcript and protein, whereas four poorly differentiated tumors had the lowest levels. The assay of oncogene products may provide new biologically relevant tumor markers for determining prognosis and guiding treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3545431     DOI: 10.1002/1097-0142(19870401)59:7<1289::aid-cncr2820590710>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  51 in total

1.  c-myc coded oncoprotein for immunotargeting. Oropharyngeal and other tumors at S.N. Medical College, Agra, India.

Authors:  V L Lahiri; D K Hazra; B R Elhence; B Mukerji; G Kalra; V Mehrotra; K Singh
Journal:  Cell Biophys       Date:  1992 Aug-Dec

2.  Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer.

Authors:  S Rowley; K M Newbold; J Gearty; M R Keighley; I A Donovan; J P Neoptolemos
Journal:  World J Surg       Date:  1990 Jul-Aug       Impact factor: 3.352

3.  Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis.

Authors:  V Sundaresan; I C Forgacs; D G Wight; B Wilson; G I Evan; J V Watson
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

4.  Increased expression of c-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's colitis.

Authors:  A J Macpherson; K A Chester; L Robson; I Bjarnason; A D Malcolm; T J Peters
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

5.  c-myc oncoprotein levels in bladder cancer.

Authors:  J R Masters; S G Vesey; C F Munn; G I Evan; J V Watson
Journal:  Urol Res       Date:  1988

6.  c-myc overexpression is a tumor-specific phenomenon in a subset of human colorectal carcinomas.

Authors:  A Viel; R Maestro; G Toffoli; G Grion; M Boiocchi
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

7.  Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumours.

Authors:  P A van Dam; J V Watson; D G Lowe; H Cox; M Curling; J H Shepherd
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

Review 8.  Genetic unraveling of colorectal cancer.

Authors:  Sabha Rasool; Vamiq Rasool; Tahira Naqvi; Bashir A Ganai; Bhahwal Ali Shah
Journal:  Tumour Biol       Date:  2014-02-27

9.  DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Authors:  Jinfei Xu; Joseph R Testa
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

10.  Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.

Authors:  M Curling; S Stenning; C N Hudson; J V Watson
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.